Loading stock data…
Theravance Biopharma (TBPH)
$16.86
Market ClosedLast close Jul 24
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Theravance Biopharma, Inc. in the Healthcare sector is trading at $16.86 with a market capitalization of $849M. Wall Street consensus targets $17.67 (3 analysts), implying a +4.8% move over the next 12 months. The stock is currently 20% below its 52-week high of $21.03, remaining 0.8% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 35) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $17.70M↓ | $45.89M↑ | $19.99M↓ | $26.20M↑ | $15.39M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.85M↓ | $20.01M↑ | -$6.46M↓ | -$2.73M↑ | -$14.43M |
| Net Income | -$4.93M↓ | $61.02M↑ | $3.62M↓ | $54.84M↑ | -$13.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary dise...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$848.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
39.42%
Volume
Today's trading volume
645,115
Recent News
Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run
Zymeworks stock has delivered a very strong 204.7% return over the past three years, yet the current valuation checks and market multiples suggest the shares may now be pricing in a lot of good news. The 204.7% three year return points to investors already paying up for Zymeworks' progress and future potential. The planned US$929m cash acquisition of Theravance Biopharma may support longer term revenue and earnings. However, integration execution and the funding structure can add risk to how...
Theravance Stock Down 3% After Zymeworks Announces Buyout
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Zymeworks agrees to buy Theravance Biopharma for $929m
The boards of both companies unanimously approved the agreement, which remains subject to shareholder and regulatory approvals.
Sector Update: Healthcare Stocks Higher Late Afternoon
Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index up 0.1% and the
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders
Theravance Biopharma shareholders will receive a contingent value right (CVR) under which they will get 80% of the net proceeds from any future license, divestiture, or monetization of ampreloxetine over the next ten years.